Y. Tony Yang, a health services and policy researcher at George Washington University, recently predicted in a JAMA Neurology editorial that a June decision by the F.D.A. will have far-reaching consequences.
The agency approved Epidiolex, the first C.B.D. prescription drug to be legally sold in the United States, for reducing seizures in rare adolescent forms of epilepsy.
“A doctor can now prescribe this off-label for other uses, which is legal and common,” Dr. Yang said. “And on the research side, this could pave